• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于异基因造血干细胞移植幸存者,我们需要了解什么?

What do we need to know about allogeneic hematopoietic stem cell transplant survivors?

作者信息

Clark C A, Savani M, Mohty M, Savani B N

机构信息

Department of Internal Medicine, Hematology and Stem Cell Transplant Section, Vanderbilt University Medical Center, Nashville, TN, USA.

The University of Tennessee Heath Science Center, College of Medicine, Memphis, TN, USA.

出版信息

Bone Marrow Transplant. 2016 Aug;51(8):1025-31. doi: 10.1038/bmt.2016.95. Epub 2016 Apr 11.

DOI:10.1038/bmt.2016.95
PMID:27064688
Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for over 70 benign and malignant hematologic and immunological processes. Over the past several decades, significant technological and post-transplant supportive advances have been made, resulting in a decrease in early transplant mortality and continued growth in the population of allo-HSCT survivors. With the expansion in the number of long-term survivors, as well as of those considering a transplant, the focus of transplant medicine has been shifted significantly to include a more prominent role for the care of the 'long-term' survivor. These patients have survived the acute critical phase of transplantation and have potentially achieved remission from their primary disease, yet allo-HSCT patients do not return to pre-transplant health status. For survivors >2 years removed, the time of transplant all-cause mortality is four- to nine-fold higher than age-matched peers within the general population. These patients represent a distinct, high-risk population that must be monitored for long-term transplant complications, including chronic GvHD (cGvHD), multi-organ dysfunctions and secondary malignancies. This article will review in a non-exhaustive manner, the approach to long-term care of an allo-HSCT recipient.

摘要

异基因造血干细胞移植(allo-HSCT)是一种对70多种良性和恶性血液及免疫性疾病具有潜在治愈作用的治疗方法。在过去几十年中,技术和移植后支持治疗取得了重大进展,导致早期移植死亡率下降,allo-HSCT幸存者数量持续增加。随着长期幸存者以及考虑进行移植的人数的增加,移植医学的重点已显著转移,将对“长期”幸存者的护理纳入更突出的角色。这些患者已度过移植的急性关键期,可能已从原发性疾病中缓解,但allo-HSCT患者并未恢复到移植前的健康状态。对于移植后超过2年的幸存者,移植后的全因死亡率比普通人群中年龄匹配的同龄人高4至9倍。这些患者是一个独特的高风险人群,必须对其长期移植并发症进行监测,包括慢性移植物抗宿主病(cGvHD)、多器官功能障碍和继发性恶性肿瘤。本文将以非详尽的方式回顾allo-HSCT受者的长期护理方法。

相似文献

1
What do we need to know about allogeneic hematopoietic stem cell transplant survivors?对于异基因造血干细胞移植幸存者,我们需要了解什么?
Bone Marrow Transplant. 2016 Aug;51(8):1025-31. doi: 10.1038/bmt.2016.95. Epub 2016 Apr 11.
2
Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.异基因造血干细胞移植后的长期结果:接受清髓性方案治疗的大队列的密切随访。
Bone Marrow Transplant. 2010 Feb;45(2):295-302. doi: 10.1038/bmt.2009.128. Epub 2009 Jul 13.
3
Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation: a retrospective study.异基因骨髓移植的健康状况、远期效应及长期生存情况:一项回顾性研究。
Intern Med J. 2014 Feb;44(2):139-47. doi: 10.1111/imj.12336.
4
A review of late complications of allogeneic hematopoietic stem cell transplantations.异基因造血干细胞移植晚期并发症综述。
Clin Transplant. 2017 Oct;31(10). doi: 10.1111/ctr.13062. Epub 2017 Aug 21.
5
Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.移植物抗宿主病与癌症和异基因造血干细胞移植后长期生存的年轻人的健康相关生活质量。
J Adolesc Young Adult Oncol. 2023 Feb;12(1):66-75. doi: 10.1089/jayao.2021.0196. Epub 2022 May 11.
6
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
7
Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.同种异体造血干细胞移植后患者的慢性移植物抗宿主病的肾脏表现。
Eur J Haematol. 2013 Aug;91(2):129-34. doi: 10.1111/ejh.12149. Epub 2013 Jun 28.
8
Heart failure after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后心力衰竭。
Int J Cardiol. 2013 Sep 10;167(6):2502-6. doi: 10.1016/j.ijcard.2012.06.021. Epub 2012 Jun 22.
9
Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality.高危异基因外周血干细胞移植受者的长期随访:移植物抗宿主病及移植相关死亡率
J Clin Oncol. 1999 Mar;17(3):806-12. doi: 10.1200/JCO.1999.17.3.806.
10
[Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].[移植物抗宿主病对26例血液系统恶性肿瘤患者移植后长期生存的影响]
Ai Zheng. 2006 Oct;25(10):1261-5.

引用本文的文献

1
Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multicentre study.急性髓系白血病和高危骨髓增生异常综合征患者在异基因造血干细胞移植前强化化疗期间的三方预处理(COHABILIT):一项创新前瞻性多中心研究方案。
BMJ Open. 2024 Mar 29;14(3):e076321. doi: 10.1136/bmjopen-2023-076321.
2
Acute graft-versus-host disease.急性移植物抗宿主病。
Nat Rev Dis Primers. 2023 Jun 8;9(1):27. doi: 10.1038/s41572-023-00438-1.
3
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients.

本文引用的文献

1
Spiritual Well-Being in Hispanic and Non-Hispanic Survivors of Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植的西班牙裔和非西班牙裔幸存者的精神健康状况
J Psychosoc Oncol. 2015;33(6):635-54. doi: 10.1080/07347332.2015.1082167.
2
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目:五、2014年辅助治疗与支持性护理工作组报告
Biol Blood Marrow Transplant. 2015 Jul;21(7):1167-87. doi: 10.1016/j.bbmt.2015.03.024. Epub 2015 Mar 31.
3
抗病毒治疗会在移植受者的癌症中产生独特的突变特征。
Cell Stem Cell. 2021 Oct 7;28(10):1726-1739.e6. doi: 10.1016/j.stem.2021.07.012. Epub 2021 Sep 7.
4
Bone Marrow Transplantation as Therapy for Ataxia-Telangiectasia: A Systematic Review.骨髓移植治疗共济失调毛细血管扩张症:一项系统评价。
Cancers (Basel). 2020 Oct 31;12(11):3207. doi: 10.3390/cancers12113207.
5
Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy.血液或骨髓移植治疗血液恶性肿瘤后认知障碍的临床和遗传风险预测。
J Clin Oncol. 2020 Apr 20;38(12):1312-1321. doi: 10.1200/JCO.19.01085. Epub 2020 Feb 21.
6
Gonadal failure among female patients after hematopoietic stem cell transplantation for non-malignant diseases.非恶性疾病造血干细胞移植后女性患者的性腺功能衰竭
Clin Pediatr Endocrinol. 2019;28(4):105-112. doi: 10.1297/cpe.28.105. Epub 2019 Oct 19.
7
[How I treat chronic graft-versus-host disease].[我如何治疗慢性移植物抗宿主病]
Zhonghua Xue Ye Xue Za Zhi. 2018 Feb 14;39(2):89-93. doi: 10.3760/cma.j.issn.0253-2727.2018.02.001.
8
Palliative care during and following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植期间及之后的姑息治疗。
Curr Opin Support Palliat Care. 2018 Mar;12(1):58-64. doi: 10.1097/SPC.0000000000000327.
9
Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.癌症患者高血糖的测量及其对健康结局的影响:挑战与机遇
Oncol Nurs Forum. 2017 Jul 1;44(4):E141-E151. doi: 10.1188/17.ONF.E141-E151.
10
Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.造血细胞移植后的长期生存:研究与照护路线图
Biol Blood Marrow Transplant. 2017 Feb;23(2):184-192. doi: 10.1016/j.bbmt.2016.11.004. Epub 2016 Nov 3.
Secondary solid cancer screening following hematopoietic cell transplantation.
造血细胞移植后的继发性实体癌筛查。
Bone Marrow Transplant. 2015 Aug;50(8):1013-23. doi: 10.1038/bmt.2015.63. Epub 2015 Mar 30.
4
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.2013年欧洲造血干细胞移植:替代供体使用的近期趋势显示单倍体相合供体增多,但脐血移植减少。
Bone Marrow Transplant. 2015 Apr;50(4):476-82. doi: 10.1038/bmt.2014.312. Epub 2015 Feb 2.
5
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目:I. 2014年诊断与分期工作组报告
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.
6
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.异基因移植中慢性移植物抗宿主病发病率上升:国际血液和骨髓移植研究中心报告
Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021. Epub 2014 Oct 30.
7
Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors.迷失在过渡阶段:血液和骨髓移植幸存者长期随访诊所的迫切需求
Biol Blood Marrow Transplant. 2015 Feb;21(2):225-32. doi: 10.1016/j.bbmt.2014.06.035. Epub 2014 Jul 3.
8
Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT).造血干细胞移植后自杀和意外死亡的增加:代表欧洲血液和骨髓移植协会(EBMT)晚期效应工作组的队列研究。
Cancer. 2013 Jun 1;119(11):2012-21. doi: 10.1002/cncr.27987. Epub 2013 Mar 19.
9
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).免疫功能低下成人患者使用 13 价肺炎球菌结合疫苗和 23 价肺炎球菌多糖疫苗:免疫接种实践咨询委员会(ACIP)的建议。
MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9.
10
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.造血细胞移植后长期生存者的推荐筛查和预防措施。
Bone Marrow Transplant. 2012 Mar;47(3):337-41. doi: 10.1038/bmt.2012.5.